Dentures, also known as false teeth are artificial teeth that are made to substitute the missing teeth. It becomes essential to replace the tooth when the tooth and its roots are beyond repair.
New York, Jan. 26, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Dentures Market Size, Share & Industry Trends Analysis Report By Type, By Usage, By End-use, By Regional Outlook and Forecast, 2022 – 2028” – https://www.reportlinker.com/p06412028/?utm_source=GNW
It is necessary to replace the missing permanent teeth otherwise teeth on either side of the space or teeth in the opposite jaw gradually move towards the gap.
These dentures are supported by the soft and hard tissues surrounding the teeth. Dentures come in varied designs and types. They are also classified into two types removable partial dentures and complete dentures. Fixed dentures design is non-removable, these prosthetic teeth are usually bonded onto the teeth by dental implants.
The design and type of the dentures also vary accordingly, whether they will be used to substitute the missing teeth on the maxillary arch or the mandibular arch. Dentures are usually adopted by people as they help in mastication or the ability to chew food, which replaces the edentulous area with prosthetic teeth.
These also help in improving aesthetics, as they give a natural appearance to the face, and wearing them also helps people to replace the missing tooth which gives support to the lips and cheeks. The loss of teeth also creates a collapsed appearance in the individual which can be corrected with the help of dentures. Dentures are very helpful in improving the pronunciation of individuals thereby increasing the self-esteem of the person to speak confidently and interact socially with a bright smile.
COVID-19 Impact Analysis
The outbreak of COVID-19 has impacted all industries worldwide. The widespread of COVID-19 mandate that healthcare organizations contribute more funds to fight the coronavirus crisis. The pandemic has crucially impacted dental care services. Governments of affected nations restricted the visits of dental patients for less important issues. However, manufacturers are now devoting more towards ways to improve and enhance patient experiences. As more innovative dentures choices are now available in the market, more patients will benefit from these innovations in the coming years. The dentures market is anticipated to benefit and grow because of these innovations.
Market Growth Factors
Technological Advancement In The Dentistry
The demand for dentures is increasing worldwide because of the adoption of digital technologies and solutions in dental services. The designing and manufacturing of digital dentures are done with the help of 3D printing technologies, computer-aided design, and computer-aided manufacturing. These cutting-edge technologies provide enormous benefits like consistency, precision, durability, and convenience. In addition, the adoption of technology helps to precisely restore dental functions such as mastication. All these factors are boosting the dentures market.
Increasing Dental Problems Among People
One of the major factors driving the growth of dentures market is the prompt increasing cases of dental cavities such as tooth loss and caries among people because of unhealthy food consumption patterns. Moreover, every nation is witnessing a rapid increase in the number and percentage of their geriatric population. According to the World Health Organization’s Global Oral Health Status Report of 2022, approximately 3.5 billion people are affected by oral diseases, worldwide. Therefore, these factors will propel the growth of the dentures market.
Market Restraining Factors
High Priced Dental Products
Over the past decades, there has been substantial development in the denture market. This development includes customization, designing, material and others. The exhausting manufacturing process and high price associated with the materials used in making dentures make the cost of these dental products considerably high. The rising cost of dental products restricts individuals living in developing countries from investing in these dental procedures. This would result in impeding the growth of the dentures market.
Type Outlook
On the basis of types, the dentures market is divided into complete and partial. In 2021, the complete segment dominated the dentures market with the highest revenue share. Complete dentures are usually recommended for people with no teeth and help in replicating gum tissues. Majorly elderly population use complete dentures. These dentures are adopted for treatments for edentulous patients. Complete dentures treatment improves the oral hygiene of the patients.
Usage Outlook
Based on usage, the dentures market is fragmented into removable and fixed. The fixed segment garnered a substantial revenue share in the dentures market in 2021. Fixed dentures are widely preferred by the patients as they are one-time investment and the requirement to remake or replace the teeth is eliminated. As constant removal is not necessary, fixed dentures also help individuals to prevent bone loss. These dentures are also preferred by individuals as they are crafted to look like natural teeth.
End Users Outlook
By end users, the dentures market is segmented into dental clinics, hospitals and others. In 2021, the hospital segment registered the maximum revenue share in the dentures market. Most individuals prefer hospitals for dental treatments due to the advanced technological tools for treatment as well as the cost efficiency. The hospitals also have trained dentists as well as technicians who are available at all times. Various hospitals also provide free dental check-ups, dental camps, dental education programmes, and online campaigns for people. Hence, the dentures market will flourish.
Regional Outlook
Region wise, the dentures market is analysed across North America, Asia-Pacific, Europe, and LAMEA. In 2021, the North America region accounted for the highest revenue share in the dentures market. This is due to an increase in the preventive approach towards oral care and hygiene, technologically advanced healthcare infrastructure, presence of independent dental clinics, growth in research &development, and rise in disposable income of the individuals. Adults in the United States have more untreated dental problems. As a result, the demand for dental prevention and restoration services will rise, the dentures market in the region would expand.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dentsply Sirona, Inc., COLTENE Holding AG, Mitsui Chemicals, Inc., Modern Dental Group Limited, Ivoclar Vivadent AG, Amann Girrbach AG, AvaDent(Global Dental Science LLC), Huge Dental, Shofu Dental GmbH, and VITA Zahnfabrik H. Rauter GmbH & Co. KG.
Strategies Deployed in Dentures Market
Nov-2022: Global Dental Science, LLC, owner of Avadent, signed an agreement with Renew, LLC, a digital, advanced full-mouth restorative treatment at an affordable cost. Under this agreement, Avadent would supply prosthetic components to Renew for its proprietary fixed-removable, full-mouth restorative process.
Oct-2022: Ivoclar announced an expanded partnership with exocad, a provider of dental CAM/CAD software. Under this partnership, companies would combine the Ivotion Denture add-on module in the exocad DentalCAD software to deliver customers with a better manufacturing workflow for the digital production of removable dentures.
Jul-2022: Dentsply Sirona released Lucitone Digital IPN 3D Premium Tooth, a printed premium denture tooth material for esthetics and durability. The product allows labs to print-on-demand denture teeth with esthetics and resistance allowed in premium-level denture teeth.
Feb-2022: Amann Girrbach released Ceramill Motion 3, an intelligent hybrid machine involved in creating fabricating dentures convenient and digital. The product is created for dry and wet operations. The five-axis milling machine operates comprehensively autonomously and could further produce both at the night and on weekends to the AG.
Jun-2021: Dentsply Sirona came into partnership with 3Shape, a developer and manufacturer of the intraoral scanners and 3Shape lab. Through this partnership, 3Shape aligns with Dentsply Sirona’s objective of developing product solutions for the need of its customers.
Jan-2021: Dentsply Sirona took over Byte, a clear aligner company. Together both companies would focus on broadening the market for orthodontic care by adding more patients with dental professionals and helping them access oral healthcare.
Sep-2019: Modern Dental Group Limited signed an agreement with The Straumann Group, an implant esthetic dentistry company, to form a joint venture with Peak Dental Solutions Hong Kong Ltd, a distribution company serving dental communities across Macau and Hong Kong. The new Company would provide a wide range of dental solutions and would have a customer base of both companies.
Mar-2018: Dentsply Sirona acquired OraMetrix, a provider of 3-D solutions created to enhance the efficiency and quality of orthodontic care. Under this acquisition, Dentsply Sirona strengthens its commitment to invest in various technologies to process innovation in the dental industry and at the same time boost its position in the marketplace and broaden its global footprint.
Scope of the Study
Market Segments covered in the Report:
By Type
• Complete
• Partial
By Usage
• Removable
• Fixed
By End-use
• Hospitals
• Dental Clinics
• Others
By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA
Companies Profiled
• Dentsply Sirona, Inc.
• COLTENE Holding AG
• Mitsui Chemicals, Inc.
• Modern Dental Group Limited
• Ivoclar Vivadent AG
• Amann Girrbach AG
• AvaDent(Global Dental Science LLC)
• Huge Dental
• Shofu Dental GmbH
• VITA Zahnfabrik H. Rauter GmbH & Co. KG
Unique Offerings
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06412028/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
__________________________
Investors did not like the latest update from Alzheimer's drug maker Cassava Sciences (NASDAQ:SAVA). After showing excellent results from the first 50 patients treated with simufilam, the company's prospective Alzheimer’s drug in an open-label mid-stage study, the results from the full 200+ patients were not as good. Patients were given 2 100mg tablets a day over the course of one year on average, and these exhibited only a minimal change in the ADAS-Cog score. In the clinical research of Alzhei
The FDA could be just months away from approving Eli Lilly and Boehringer Ingelheim's drug candidate to treat a common condition.
Risk and reward often travel hand-in-hand, making the stock market both lucrative and dangerous. Among the best exemplars of this axiom are the penny stocks, those equities priced at $5 or less. With that low price comes the potential for extreme gains, as even an incrementally small price increase will translate to a high percentage gain. However, before jumping right into an investment in a penny stock, Wall Street pros advise looking at the bigger picture and considering other factors beyond
Equity markets are entirely unpredictable in the short run. The biotech industry is a great place to look for stocks that can survive down markets and be successful over long periods since the drugs these companies develop are so critical to their customers' lives. Let's look at two biotech stocks to buy today and hold on to for a while: Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA).
According to the longest happiness study in history, we all need to be strengthening our relationships.
Shares of Pliant Therapeutics (NASDAQ: PLRX) were skyrocketing 61% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced positive interim results on Sunday from a phase 2a clinical study evaluating bexotegrast (PLN-74809) in treating idiopathic pulmonary fibrosis (IPF). Pliant reported that patients receiving a 320 mg dose of bexotegrast achieved a statistically significant increase in forced vital capacity (FVC) at four, eight, and 12 weeks of treatment.
Is Pfizer stock a buy or a sell after getting a downgrade on its falling Covid-tied sales? Is PFE stock a buy or a sell right now?
Until he became an unwitting flash point in the nation's culture wars, Richard Trumka Jr. was little known to most Americans, despite being the son of a famous labor leader. But less than three weeks ago, this member of the Consumer Product Safety Commission was thrust into the public limelight. In an interview with Bloomberg News, Trumka said his commission was considering regulations – or even a ban – on new gas stoves because of concerns about their harmful indoor air pollution.Subscribe to T
The philanthropist and former Microsoft chief discusses how the world responded to the pandemic and offers some conclusions.
Is Merck stock a buy or a sell after Keytruda succeeded in one study but failed in another in late January? Is MRK stock a buy or a sell?
Doctors initially told Dave Whitford, 49, he was suffering from an inner ear infection caused by an insect bite
Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.
(Bloomberg) — Federal agencies are questioning Snapchat’s role in the spread and sale of fentanyl-laced pills in the US as part of a broader probe into the deadly counterfeit drugs crisis.Most Read from BloombergHindenburg vs Adani: The Short Seller Taking On Asia’s Richest PersonNYSE Mayhem Traced to a Staffer Who Left a Backup System RunningWe Asked ChatGPT to Make a Market-Beating ETF. Here’s What HappenedHindenburg’s Short Sell Call Shaves $12 Billion Off Adani StocksAgents from the Federal
Today, Manulife announced Cleveland Clinic Canada as the new Medical Director for its Group Benefits operations. Cleveland Clinic Canada will bring global healthcare expertise to advise Manulife and support their ongoing commitment to helping its approximately 5 million group benefits customers manage personal health issues, and navigate Canada's stretched and often complex healthcare system. This relationship reflects another significant step in Manulife's goal to help Canadians live longer, he
When managers are more open about their own mental health journey, experts say it can help create a more inclusive and supportive environment.
MARKET PULSE AstraZeneca (AZN) (UK:AZN) said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophylaxis of COVID-19, citing its lack of effectiveness against the currently circulating variants.
Eva Longoria just dropped a bikini photo on Instagram and she's mega-sculpted, from her abs to her legs. The actress enjoys doing mini trampoline workouts.
A massive, coordinated scheme to sell false and fraudulent nursing degree credentials has been brought down by a joint federal law enforcement operation, Justice Department officials said Wednesday. As first reported by ABC News, officials said the scheme involved peddling more than $100 million worth of bogus nursing diplomas and transcripts over the course of several years — fake credentials that were sold to help "thousands of people" take "shortcuts" toward becoming licensed, practicing nurses. Officials said the forged diplomas and transcripts were sold from what had been accredited schools to aspiring nurses, in order to help candidates bypass the qualifying requirements necessary to sit for the national nursing board exam.
New data from one U.S. Centers for Disease Control and Prevention (CDC) database shows a possible stroke risk link for older adults who received an updated Pfizer/BioNTech COVID-19 booster shot, but the signal is weaker than what the agency had flagged earlier in January, health officials said on Thursday. U.S. Food and Drug Administration officials said they had not detected a link between the shots and strokes in two other safety monitoring databases. The new data was presented at a meeting of outside experts that advise the FDA on vaccine policy.
The Food and Drug Administration (FDA) had limited Evusheld's use earlier this month for the same reason and the agency's Thursday announcement sent U.S. shares of London-based AstraZeneca down 1.31% to $65.75. Omicron subvariant XBB.1.5 has been spreading rapidly in the country since December and it made up nearly half of all U.S. COVID-19 cases last week, according to government data.